Natera to Present 20 Abstracts Highlighting Signatera Cancer Testing at ESMO 2026 Congress
Natera, Inc. (NASDAQ:NTRA) announced that 20 abstracts showcasing its diagnostic technology will be presented at the 2026 European Society for Medical Oncology (ESMO) Annual Congress in Madrid, Spain, scheduled for October 23–26. The presentations focus on the company's ultrasensitive molecular residual disease (MRD) test, Signatera Genome with Phased and Structural Variants, which can detect circulating tumor DNA at levels significantly below 1 part per 10 million.
The clinical data across multiple cancer types demonstrates how serial testing with Signatera can influence treatment decisions and predict outcomes. In the phase III SAGITTARIUS trial for colon cancer, test results led physicians to alter treatment plans for one-third of patients, with 87% undergoing therapy de-escalation after showing negative MRD results. Additionally, results from the ICONIC trial in gastroesophageal cancer showed that Signatera detected disease recurrences with a median lead time of more than 7.3 months compared to standard imaging methods.
Investors and healthcare providers will watch the full presentations during the ESMO Congress starting October 23, 2026. The upcoming findings may further support the adoption of liquid biopsy testing in routine clinical oncology and solid organ transplantation planning.
Key points
- Natera will present 20 abstracts at the ESMO 2026 Annual Congress in Madrid from October 23 to 26.
- Signatera Genome technology achieved an analytical limit of detection below 1 part per million, detecting ctDNA below 1 part per 10 million.
- In the SAGITTARIUS colon cancer trial, Signatera results changed treatment plans for 33% of patients, leading to de-escalation in 87% of those cases.
- Signatera detected gastroesophageal cancer recurrences with a median lead time exceeding 7.3 months compared to standard imaging.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What is Natera presenting at ESMO 2026?
Natera is presenting 20 abstracts featuring its oncology diagnostics and Signatera molecular residual disease technology at the ESMO Congress in Madrid from October 23 to 26, 2026.
How sensitive is Natera's Signatera Genome assay?
The Signatera Genome assay with phased and structural variants has an analytical limit of detection below 1 part per million and can detect circulating tumor DNA significantly below 1 part per 10 million.
How did Signatera impact colon cancer treatment decisions in the SAGITTARIUS trial?
Signatera test results influenced doctors to change pre-planned treatment for one in three colon cancer patients, with 87% of those changes involving treatment de-escalation due to negative results.